静脉注射乌拉地尔对治疗充血性心力衰竭疗效的评价

目的评价在常规药物洋地黄、利尿剂、血管紧张素转换酶抑制剂(ACEI)及β受体阻滞剂治疗充血性心力衰竭(CHF)α1受体阻滞乌拉地尔的临床疗效比较。方法选择慢性CHF患者85例,分为:对照组(39例)常规给予洋地黄、利尿剂、ACEI及β受体阻滞剂治疗;治疗组(46例)在常规药物洋地黄、利尿剂、血管紧张素转换酶抑制剂(ACEI)及β受体阻滞剂基础上加用新型的α1受体阻滞剂乌拉地尔(Urapidil)持续静脉注射,速度:50～100μg/min,连续应用5～7d。治疗前后评价心脏功能、心率、血压以及心脏收缩功能指标。结果治疗组和对照组的有效率分别为84.8%、59.0%(P<0.05);两组显效病例为:19(41.3%)∶9(23.1%),P<0.05;有效病例无明显差异:20(43.5%)∶14(35.9%),P>0.05;无效病例治疗组明显少于对照组:7(15.2)∶16(41.0),P<0.05;治疗组治疗后血压明显下降,心率明显减慢,收缩功能指标明显改善;治疗后组间对照:治疗组心率、血压、心脏收缩功能指标明显优于对照组。结论在常规药物洋地黄及利尿剂、ACEI及β受体阻滞剂基础上治疗,静脉注射乌拉地尔CHF,在改善临床症状和血液动力学指标和心脏收缩功能方面效果良好,并具有良好的安全性和可靠性。

Assessment on Curative Effect of Treatment for Congestive Heart Failure Injected with Urapidil

Objective To assess the clinical curative effect in digitalis, diuretics, ACEI and β-receptor blocker in treatment of CHF. Methods 85 cases of CHF patient were divided into control group (39 cases) treated with digitalis, diuretics, ACEI and β-receptor blocker and therapy group (46 cases) treated with urapidil on base of digitalis, diuretics, ACEI and β-receptor blocker for 5～7 at 50～100 ug/min. The heart function, HR, Bp and contract data were observed. Results They were 84.8% in excellent rate, 41.3% in effective rate and 15.2% in non-effective rate in therapy group. They were 59.0% in excellent rate, 23.1% in effective rate and 41.0% in non-effective rate in control group. The relative data was improved during treatment in therapy group and better than control group. Conclusion The urapidil could treat CHF better on the base of routine therapy with good effect, safe and reliable.